Dorothee Ambrosius joined Boehringer Ingelheim in 2003 and she is currently heading the downstream development department at Boehringer Ingelheim in Biberach. The downstream department is responsible for the development of robust and economic purification processes for biopharmaceutical medicines derived from mammalian cell culture starting from bench scale up to 2000L GMP scale for generation of clinical grade material. Dorothee has a broad expertise in Biochemistry / Protein Chemistry and over 15 years of experience in identification and development of novel biopharmaceutical proteins (antibodies and proteins factors) from different sources. She completed her PhD in Biology at the RWTH in Aachen and joint Boehringer-Mannheim, Biotechnology Research Center in 1989. She held several research management positions at Boehringer-Mannheim and Roche in the area of recombinant protein production. She was responsible for development of novel therapeutic proteins including protein refolding, protein characterization and process development as well as for structural elucidation and assay development for identification and generation of new low molecular weight compounds.

Dr Burton is the Chief Executive Officer of Prometic Biosciences Ltd (PBL), a wholly owned subsidiary of ProMetic Life Sciences Inc. PBL is focused on the development of materials and technology used in a variety of bio-pharmaceutical applications, most notably the manufacture of therapeutic proteins (from native and recombinant sources) and bio-contaminant removal. Dr Burton gained his Ph.D. at the University of Cambridge, U.K. researching novel affinity ligands for use in protein purification and as artificial coenzymes. He joined Delta Biotechnology Ltd (now NovozymesDelta) in 1986 as a research scientist and moved to Affinity Chromatography Ltd in 1988 as Research Manager prior to his appointment as R&D Director in 1993 following the establishment of a successful R&D group which won the Queens Award for Technological Achievement in 1996. Affinity Chromatography Ltd became a wholly owned subsidiary of Prometic Life Sciences in 1999 subsequent to which Dr Burton held the positions of Vice President, Research and Development and Executive Vice President/Chief Scientific Officer until his appointment as CEO in February 2006.

Patrick Carl, Head of Capacity Management, supports Merck Serono’s Technical Operations management in decision making of long-term product, development activity, and volume allocation to optimize global asset and capacity utilization across all production and development activities. Patrick Carl joined Merck KGaA’s Inhouse Consulting for a Graduate Development Program. He is a mechanical engineer of Technische Universität München (TUM) with a focus on production management. He conducted his masters’ thesis research at MIT, and holds an MBA from RWTH Aachen University.

Mr. Downey is president and managing director of HighTech Business Decisions, a consulting company that specializes in market research for business-to-business biotechnology, pharmaceutical manufacturing, medical and electronic products. Mr. Downey has over 25 years of experience and held various positions in marketing, sales, strategy and finance. Mr. Downey has a Masters in Business Administration form Washington University in St. Louis and Bachelors from the University of Michigan in Ann Arbor.

Igor Fisch is the Chief Executive Officer of Selexis and Chairman of the Board of Directors. He is an accomplished protein chemist and molecular biologist. After completing his post-doctoral studies at the Medical Research Council in Cambridge, UK, he joined the Center for Biotechnology UNIL-EPFL as a group leader, working in the field of molecular evolution and peptide discovery. In parallel to his research and teaching activities, he received the De Vigier Prize and the NETS Best Prize with training in entrepreneurship both at the EPFL in Lausanne and at the Babson College in Boston, USA

- Post-doc at Boehringer Mannheim, Penzberg, Germany (now Roche Diagnostics) - 1996 - 2003 Head of Pilot Plant Protein Purification, Process Development department at Chiron Behring, Marburg, Germany - March 2002 appointment as Professor for Bioanalytics at the Mannheim University of Applied Science - Since 2004 Head of the Institute for Biochemistry - Since 2004 Director of the Steinbeis Transfer Centre "Technical Consulting"

Dr. Gilbert Gorr is one of the leading developers of the moss photo bioreactor and has been scientific leader of greenovation Biotech GmbH since October 2000. He studied biology and chemistry and obtained his doctorate at the University of Hamburg for his thesis about the employment of moss as expression system (human VEGF). Dr. Gilbert Gorr joined the management team as CSO in 2002.

Dr. Fadel Hamed PROP Operational Excellence An effective problem solver with an extensive background in process improvement, lean, and six sigma. Fadel has more than 12 years of experience in multiple industries including semiconductor, fiberoptics, and now biotechnology. Prior to joining Genentech, Fadel worked at Amgen, IBM, and Lambda Optics. Fadel’s background combines skills in operations, manufacturing , quality, technical management, and strong leadership. He is a frequently requested speaker at International conferences. Fadel holds a doctorate in mechanical engineering from UC Berkeley and he is an ASQ certified six sigma black belt and quality engineer

Hans Huber has been working as a bioprocess engineer in the Process Science Group of Boehringer Ingelheim Austria, Vienna since 1999. In his current position, he is a Technology Agent for biopharmaceutical production, in which he is responsible for innovation management and the implementation of enabling technologies. From 2002 – 2006, he was head of the Unit Microbial Fermentation Development, where he was responsible for development and scale-up of fermentation processes for recombinant proteins and plasmids. Dr. Huber holds a PhD in Biotechnology from the University of Natural Resources and Life Sciences / Vienna and did his thesis on industrial manufacturing of therapeutic plasmid DNA.

Dr Kadouri is one of the leading scientists in Industrial biotechnology with worldwide reputation. He has 15 years of experience as R&D Director and world wide Process development Director in Serono International. Until 2007 Dr. Kadouri was the Chairman of ACTIP (Animal Cell Technology Industrial Platform), an important European Organization of the major Biotech Companies in Europe. He is a member of several Scientific Advisory Boards of a leading biotech companies in US, Europe and Israel. He is the CEO of Rainbow Biotechnologies-Sarl and the Chief technology advisor of Brainstorm Cell Therapeutics, a leading company in Neurogenerative therapy. He is a world expert in process development, on setting up strategies for technology transfer and fast truck to Clinic/market. Prior to working in the industry Dr. Kadouri spent many years in a leading research Institutes and Universities. He has published large number of papers in life science and biotechnology and holds several applied patents. Dr. Kadouri is a key guest speaker in many major international conferences in biotechnology at the US and Europe.

Bo Kara is Head of Expression and Cell Sciences at Avecia Biotechnology. This comprises the Molecular Biology/Gene Expression , Microbial Fermentation and Mammalian Cell Culture process development/scale-up groups. Bo has 20 years expertise with ICI, Zeneca, AstraZeneca and Avecia, in designing research and development programmes to develop scaleable and validatable manufacturing processes for recombinant protein products. He has developed a keen understanding of the technical, regulatory and commercial issues faced at each stage of the development of manufacturing process for biopharmaceuticals. Avecia’s biologics capabilities, centred at Billingham UK, include process development services in microbial and mammalian cell derived protein therapeutics and “fast track” cGMP contract manufacture of microbial derived protein-based pharmaceuticals- clinical supply through to large scale commercial supply. Prior to joining Avecia Biotechnology in August 2000, Bo Kara was Team Leader, Biotherapeutic Process Development and Technology Transfer at AstraZeneca Pharmaceuticals, UK for both microbial and cell culture derived biotherapeutics. Bo Kara was previously a Scientist at BRF International, UK involved with brewing research and development (1986-1987).

Hans-Peter received his Ph.D. in Molecular and Cell Biology at the Albert-Ludwigs University of Freiburg, Germany, working in conjunction with the University Clinic and the Max-Planck Institute of Immunology. During 1994/5 he was Post Doc at the Max Planck Institute of Immunology, Freiburg, focused on the characterization of primary human monocytes and macrophages. Hans-Peter joined Novartis AG / Biotechnology Development in 1995 as a lab head in cell and molecular biology. As he was responsible for the development of cell lines, cell banking and molecular biological analytics, he was involved in the registration procedures for biopharmaceuticals. From 1999 to 2005 he served as a group head in “Cell and Molecular Biology”, where he was responsible for the development of expression vectors and production cell lines and all cGMP related aspects. During 2005 to 2006 he served as a head of “Protein Expression Technologies”, focused on the evaluation and development of new expression technologies for glycosylated biopharmaceuticals. In 2006 he joined the management team of Biotechnology Development as a Technical Project Leader and is responsible for the mammalian cell line as well as the alternative expression platforms

- Born 06.04.1950 in Bruck/Austria - Study of Chemistry and Biochemistry at Technical University in Graz/Austria - Ph. D. in Technical Chemistry 1977 - Associate Professor at University Linz/Austria since 1984 - Various functions in QA, Licensing, Business Development, R&D at Biochemie/Austria from 1977 – 2003 - Since 2003 Head of Biotech Cooperations at Sandoz GmbH, Austria

Dr. Nixon is a senior director of research at Dyax, responsible for Biochemistry activities within the discovery research group. In this role he oversees production, purification and characterization of isolates identified from the Dyax phage display libraries which include peptides, Kunitz domains and antibodies. Additionally he is responsible for production of target antigens to support selection and screening of the Dyax phage display libraries. Prior to joining Dyax in 1999, Dr. Nixon completed a post-doctoral fellowship in the laboratory of Prof. S.J. Benkovic, in the Department of Chemistry at Pennsylvania State University, where he was involved in the development of techniques to facilitate enzyme engineering. Dr. Nixon earned his Ph.D. from the University of London for studies completed at the MRC’s National Institute for Medical Research.

Over 22 years of industry experience [7 years at Biogen & Biogen-Idec] related to the development of biopharmaceuticals [protein-based] and cells as products [biotech approaches for hu-hepatocytes and hu-dermis & -epidermis cells]. Long-term experience with CC-based vaccine development and production. Since the merger between Biogen & Idec responsible for all biologics process development, spanning over cell culture, protein biochemistry, protein formulation, analytical development. Major activities also encompassing methods & strategy harmonization between the two legacy companies, and “horizontal integration efforts” between BPD-MS/MFG and research-BPD. Head of manufacturing alliances during my years with Boehringer-Ingelheim, before that, head of cell technology and GMP pilot plant operation, head of several inter-company projects [CMO]. Co-leader and organizer of various cell culture related organizations [international / national, as are ESACT, DECHEMA, CC Engineering] Over 70 publications, 4 patents and numerous presentations at international forums.

Dr. Sadettin Ozturk is the head for Bioprocess Technology at Centocor R&D Inc. His group is responsible for process and technology development, process scale-up and optimization for cell culture based pharmaceuticals. Prior to joining Centocor Inc., Sadettin worked at GlaxoSmithKline as Senior Technology Manager where he led cell culture activities in BiopharmaceuticaTechnologies Department. His group was responsible for technology and process transfer from R&D to Production, process scale-up and optimization, technical support to Manufacturing, and implementation of new technologies.

Laurens finished his PhD in Biotechnology in 1994 at the University of Utrecht, The Netherlands, studying yeasts as production organism for enzymes and antibodies. He then worked for three years within the Unilever Detergents business as Project Manager incorporating enzymes (proteases, lipases) into Detergent products. In 1997 he joined BAC, a Unilever spin-off company, focused on manufacturing and using llama single domain antibodies (also known as nanobodies) as affinity ligands for purification of Biopharmaceuticals (CaptureSelect affinity products). Since the Unilever spin-off in 2005 Laurens is the CEO of BAC BV.

Andrew Sinclair founded BioPharm Services in December 1998 to develop a technology based services business focused on all aspects of biopharmaceuticals manufacturing. The company has developed software tools and databases for economic analysis and optimisation of bioprocesses and manufacturing operations. It also has developed unique insights into the market biomanufacturing market dynamics. Biopharm Services is six years old it has 12 employees based both in the UK and the US. Andrew Sinclair has over 20 years experience within the biopharmaceutical sector working for manufacturing operations (Lonza, Eli Lilly, GlaxoSmithKline) and contractors (Kvaerner, Jacobs engineering). He has been responsible for design, building and operation of biomanufacturing facilities. Prior to setting up Biopharm Services Andrew was the Director of Engineering and Logistics and Lonza Biologics.

Charles H. Squires received his doctorate in biology from Purdue University in 1979. From 1979 through 1981 he was a post-doctoral associate at Cornell University studying microbial gene regulatory mechanisms. He spent the next 12 years at Synergen Inc in Boulder, Colorado where he held a number of research and leadership positions in the discovery and development of protein pharmaceuticals. In 1993, Dr. Squires joined Energy Biosystems in The Woodlands, Texas where he led biocatalyst development. He joined The Dow Chemical Company in San Diego in 1999 as senior director for biotechnology research and development. He is currently leading efforts by Dowpharma to develop and commercialize technologies for the low cost production of protein pharmaceuticals and vaccines in the bacterium Pseudomonas fluorescens, Pfenex Expression Technology.

Professor Rolf G Werner is Managing Director of the Corporate Division for Biopharmaceuticals at Boehringer Ingelheim GmbH and responsible for the strategic orientation and the worldwide business of biopharmaceuticals. He joined Boehringer Ingelheim in 1973, after obtaining his PhD at the University of Tübingen. In 1990 he was appointed as professor at the Faculty of Biology at the same university. Throughout his time at Boehringer Ingelheim, he has worked in positions of increasing responsibility in the biopharmaceutical division before being promoted to Managing Director in 2000. In January 2004, he received an honorary doctor degree from the University of Chiang Mai in Thailand.

After studying Process Engineering at the University of Hannover (academic degree "Dipl.-Ing."), I started my job career in 1990 as Junior Sales Engineer for Gas Monitoring System at Messrs. Drägerwerk Germany. After 2 years I moved to Messrs. DIESSEL GmbH, Germany as International Sales Manger for pharmaceutical production system for the preparation of any type of liquid pharmaceutical drugs. In 2001 I took over the responsibility as Sales Director Pharma & Biotech. In 2002 I changed to B. Braun Biotech International GmbH, Germany as Sales Director Fermentation Projects. I worked worldwide for custom fermentation projects. Since 1.02.2004 I’m working for Perbio Science. I firstly started as Business Development Manager for single use Bioprocess Container (BPC). In August I was promoted to the function of the Industrial Sales Director Europe, which I’m still holding till today. Part of my responsibilities in the past was the organization of several customer seminars as well as the participation as speaker in different national and international seminars, like APV (Germany), Concept (Germany) and ISPE (Europe, Zurich).